Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
The Lancet. Respiratory Medicine
|
August 2, 2025
Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials
Nicole Mayer-Hamblett, Natanya R Kerper, John P Clancy, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
February 27, 2025
A Systematic Review of the Variability of Ventilation Defect Percent Generated From Hyperpolarized Noble Gas Pulmonary Magnetic Resonance Imaging
Vanessa M Diamond, Laura C Bell, Jeffrey N Bone, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Jennifer L Goralski, Jordana E Hoppe, Marcus A Mall, et al.
The European Respiratory Journal
|
May 2, 2024
A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
Valerie Waters, Michelle Shaw, Lucy Perrem, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study
Claire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Infectious Diseases
|
January 23, 2026
Management of critical illness in an adolescent caused by highly pathogenic avian influenza A(H5N1) virus infection in British Columbia, Canada
Elspeth MacBain, Ashraf Znait, Linda Edwards, et al.
JAMA Network Open
|
April 11, 2025
Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus
Nardin Kirolos, Haifa Mtaweh, Rohini R Datta, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Edith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The Journal of Experimental Medicine
|
May 20, 2025
A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis
Maryam Vaseghi-Shanjani, Mehul Sharma, Pariya Yousefi, et al.
Magnetic Resonance in Medicine
|
September 3, 2021
Protocols for multi-site trials using hyperpolarized <sup>129</sup> Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the <sup>129</sup> Xe MRI clinical trials consortium
Peter J Niedbalski, Chase S Hall, Mario Castro, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
The Lancet. Respiratory Medicine
|
August 2, 2025
Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials
Nicole Mayer-Hamblett, Natanya R Kerper, John P Clancy, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
February 27, 2025
A Systematic Review of the Variability of Ventilation Defect Percent Generated From Hyperpolarized Noble Gas Pulmonary Magnetic Resonance Imaging
Vanessa M Diamond, Laura C Bell, Jeffrey N Bone, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Jennifer L Goralski, Jordana E Hoppe, Marcus A Mall, et al.
The European Respiratory Journal
|
May 2, 2024
A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
Valerie Waters, Michelle Shaw, Lucy Perrem, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study
Claire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Infectious Diseases
|
January 23, 2026
Management of critical illness in an adolescent caused by highly pathogenic avian influenza A(H5N1) virus infection in British Columbia, Canada
Elspeth MacBain, Ashraf Znait, Linda Edwards, et al.
JAMA Network Open
|
April 11, 2025
Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus
Nardin Kirolos, Haifa Mtaweh, Rohini R Datta, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Edith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The Journal of Experimental Medicine
|
May 20, 2025
A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis
Maryam Vaseghi-Shanjani, Mehul Sharma, Pariya Yousefi, et al.
Magnetic Resonance in Medicine
|
September 3, 2021
Protocols for multi-site trials using hyperpolarized <sup>129</sup> Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the <sup>129</sup> Xe MRI clinical trials consortium
Peter J Niedbalski, Chase S Hall, Mario Castro, et al.
Page
of 7